Found 265 articles
KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced that the Company will host a conference call and live audio webcast on Thursday, May 12, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the first quarter 2022.
KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
KemPharm, Inc. today announced that the first subject has been dosed in a Phase 1 clinical trial designed to assess the relative cardiovascular safety of serdexmethylphenidate (SDX) compared to immediate-release and long-acting formulations of Ritalin® (racemic methylphenidate).
KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today reported its financial results for the fourth quarter and year ended December 31, 2021.
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, will deliver a virtual presentation at Maxim’s 2022 Virtual Growth Conference being held March 28-30, 2022.
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
KemPharm, Inc. today announced that the Company has completed its analysis of the full data set from its Phase 1 clinical trial exploring the safety and pharmacokinetics (PK) of serdexmethylphenidate (SDX) delivered at doses higher than those previously studied.
KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)
KemPharm, Inc. (NasdaqGS: KMPH) (the Company, or KemPharm), today announced that the Company has earned a $1.975 million fee from Corium, Inc., (Corium), a portfolio company of Gurnet Point Capital, following the approval of Corium’s product ADLARITY® (donepezil transdermal system) by the U.S. Food and Drug Administration (FDA) on March 11, 2022.
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, March 30, 2022, 5:00 p.m. ET.
Acura Pharmaceuticals, Inc. announced an amendment to its License, Development and Commercialization Agreement regarding Acura’s LIMITx™ LTX-03 product candidate with Abuse Deterrent Pharmaceuticals, LLC to extend the FDA Acceptance Date for LTX-03 to December 31, 2022.
KemPharm Positioned to Submit IND Application for KP1077 for Idiopathic Hypersomnia by Mid-2022.
KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy
KemPharm, Inc. announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders detailing the company’s strategic focus on Central Nervous System /Rare Disease indications, as well as an updated clinical development strategy.
KemPharm, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, January 19, 2022, at 4:30 p.m. ET, to discuss the Company’s strategy for advancing and expanding its development pipeline.
KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference
KemPharm, Inc., announced that research involving serdexmethylphenidate, the company’s proprietary prodrug of d-methylphenidate, will be featured in two poster presentations during the American Professional Society of ADHD and Related Disorders 2022 Annual Conference being held virtually January 13-16, 2022.
KemPharm, Inc. announced today the company is participating in BIO Partnering @ JPM, which is being held virtually alongside the J.P. Morgan 40th Annual Healthcare Conference 2022.
12/20/2021It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
KemPharm, Inc. announced today its Board of Directors has authorized a program to repurchase up to $50 million of the Company’s outstanding stock.
KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”
KemPharm, Inc. announced today top-line results from its clinical trial exploring the safety and pharmacokinetics of serdexmethylphenidate (SDX) delivered at doses higher than those studied as part of the AZSTARYS® development program.
KemPharm, Inc. today announced that it has been named the 2021 David J. Gury Company of the Year by BioFlorida.
KemPharm, Inc., a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced its common stock has been added to the Nasdaq Biotechnology Index in accordance with an annual reconstitution of the index.
First Wave BioPharma’s CEO and President, James Sapirstein, to Participate in CEO Panel Discussion at 2021 BioFlorida ConferenceIndustry leaders to discuss the trends fueling the future of Florida’s life sciences industry
First Wave BioPharma, Inc., today announced that James Sapirstein, Chairman, CEO and President of First Wave BioPharma, will participate in a CEO discussion panel at the 2021 BioFlorida Conference taking place December 8-10, 2021.